Variables associated with patient-reported outcomes in persons with chronic myeloid leukemia receiving tyrosine kinase-inhibitor therapy
- 304 Downloads
Explore patient-reported outcomes (PROs), including health-related quality of life (HRQoL), satisfaction with therapy, impact of the therapy on work and daily life, and concerns related to the therapy and identify variables associated with PROs in persons with chronic myeloid leukemia (CML) receiving tyrosine kinase inhibitors (TKIs).
Across-sectional questionnaire was distributed to adults with chronic phase CML and answered anonymously. SF-36 Health Survey was used to measure HRQoL. Our focus was on the physical component summary (PCS) and mental component summary (MCS) components.
Data from 819 respondents receiving TKI-therapy ≥3 months and achieving a complete cytogenetic response were analyzed. Median age was 42 years (range 18–88 years). 652 (80%) were receiving imatinib. Median TKI-therapy duration was 36 months (range 3–178 months). 629 (77%) paid some or all of their TKI costs. In multivariate analyses, female sex, increasing age, lower education level, increasing co-morbidities, concomitant medication, ≥3 symptoms, moderate or severe symptom, switch from imatinib to a second-generation TKI, and higher annual out-of-pocket expense of TKI were significantly associated with lower PCS and/or MCS. However, TKI-therapy duration 3–7 years was significantly associated with better well-being. Higher PCS or MCS score was significantly associated with higher satisfaction level with TKI-therapy and less impact of TKI-therapy on subject’s daily life and work. In addition, adverse impact on daily life and work was significantly associated with more interests in TKI-therapy-related issues.
Social-economic and clinical variables were significantly associated with PROs in persons with CML receiving TKI-therapy.
KeywordsChronic myeloid leukemia Tyrosine kinase inhibitors Patient-reported outcomes
Compliance with ethical standards
This study was funded by the National Natural Science Foundation of China (No. 81370637).
Conflict of interest
Author RPG is a part-time employee of Celgene Corporation, Summit, NJ, USA. The remaining authors declare no conflict of interest.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Because the survey used anonymous questionnaires, the Ethics Committee of Peoples Hospital determined informed consent of participants was not required.
- Cortes JE, Lipton JH, Miller CB, Busque L, Akard LP, Pinilla-Ibarz J et al (2016) Evaluating the impact of a switch to nilotinib on imatinib-related chronic low-grade adverse events in patients with CML-CP: the ENRICH study. Clin Lymphoma Myeloma Leuk 16(5):286–296CrossRefPubMedPubMedCentralGoogle Scholar
- Efficace F, Breccia M, Saussele S, Kossak-Roth U, Cardoni A, Caocci G et al (2012) Which health-related quality of life aspects are important to patients with chronic myeloid leukemia receiving targeted therapies and to health care professionals? GIMEMA and EORTC Quality of Life Group. Ann Hematol 91(9):1371–1381CrossRefPubMedGoogle Scholar
- Gu´erinA, Chen L, Ionescu-Ittu R, Marynchenko M, Nitulescu R, Hiscock R (2014) Impact of low-grade adverse events on health-related quality of life in adult patients receiving imatinib or nilotinib for newly diagnosed Philadelphia chromosome positive chronic myelogenous leukemia in chronic phase. Curr Med Res 30(11):2317–2328CrossRefGoogle Scholar
- Hahn EA, Glendenning GA, Sorensen MV, Hudgens SA, Druker BJ, Guilhot F et al (2003) IRIS Investigators. Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS Study. J Clin Oncol 21(11):2138–2146CrossRefPubMedGoogle Scholar
- Hirji I, Gupta S, Goren A, Chirovsky DR, Moadel AB, Olavarria E et al (2013) Chronic myeloid leukemia (CML): association of treatment satisfaction, negative medication experience and treatment restrictions with health outcomes, from the patient’s perspective. Health Qual Life Outcomes 11:167CrossRefPubMedPubMedCentralGoogle Scholar
- Kekäle M, Peltoniemi M, Airaksinen M (2015) Patient-reported adverse drug reactions and their influence on adherence and quality of life of chronic myeloid leukemia patients on per oral tyrosine kinase inhibitor treatment. Patient Prefer Adherence 9:1733–1740CrossRefPubMedPubMedCentralGoogle Scholar
- Mesa RA, Miller CB, Thyne M, Mangan J, Goldberger S, Fazal S et al (2016) Differences in treatment goals and perception of symptom burden between patients with myeloproliferative neoplasms (MPNs) and hematologists/oncologists in the United States: findings from the MPN landmark survey. Cancer. doi: 10.1002/cncr.30325 (Epub ahead of print] PubMed PMID: 27690182) Google Scholar
- National Comprehensive Cancer Network, NCCN Clinical Practice Guidelines in Oncology: Chronic Myelogenous Leukemia Version 1 (2016) Fort Washington PA. National Comprehensive Care Network. http://www.nccn.Org/professionals/physician_gls/pdf/cml.pdf. Accessed 26 March 2016
- Sasaki K, Strom SS, O’Brien S, Jabbour E, Ravandi F, Konopleva M et al (2015) Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials. Lancet Haematol 2(5):e186–93CrossRefPubMedPubMedCentralGoogle Scholar